Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Telmisartan Market, by Indication
1.4.2 Europe Telmisartan Market, by Distribution Channel
1.4.3 Europe Telmisartan Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Europe Telmisartan Market by Indication
3.1 Europe Hypertension Market by Country
3.2 Europe Cardiovascular Risk Reduction Market by Country
Chapter 4. Europe Telmisartan Market by Distribution Channel
4.1 Europe Hospital Pharmacies Market by Country
4.2 Europe Drug Stores and Retail Pharmacies Market by Country
4.3 Europe Online Pharmacies Market by Country
Chapter 5. Europe Telmisartan Market by Country
5.1 Germany Telmisartan Market
5.1.1 Germany Telmisartan Market by Indication
5.1.2 Germany Telmisartan Market by Distribution Channel
5.2 UK Telmisartan Market
5.2.1 UK Telmisartan Market by Indication
5.2.2 UK Telmisartan Market by Distribution Channel
5.3 France Telmisartan Market
5.3.1 France Telmisartan Market by Indication
5.3.2 France Telmisartan Market by Distribution Channel
5.4 Russia Telmisartan Market
5.4.1 Russia Telmisartan Market by Indication
5.4.2 Russia Telmisartan Market by Distribution Channel
5.5 Spain Telmisartan Market
5.5.1 Spain Telmisartan Market by Indication
5.5.2 Spain Telmisartan Market by Distribution Channel
5.6 Italy Telmisartan Market
5.6.1 Italy Telmisartan Market by Indication
5.6.2 Italy Telmisartan Market by Distribution Channel
5.7 Rest of Europe Telmisartan Market
5.7.1 Rest of Europe Telmisartan Market by Indication
5.7.2 Rest of Europe Telmisartan Market by Distribution Channel
Chapter 6. Company Profiles
6.1 Abbott Laboratories
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Segmental and Regional Analysis
6.1.4 Research & Development Expense
6.2 Aurobindo Pharma Limited
6.2.1 Company Overview
6.2.1 Financial Analysis
6.2.2 Regional Analysis
6.2.3 Research & Development Expense
6.2.4 Recent strategies and developments:
6.2.4.1 Approvals:
6.2.4.2 Acquisition and Mergers:
6.3 Boehringer Ingelheim International GmbH
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Segmental and Regional Analysis
6.3.4 Research & Development Expense
6.3.5 Recent strategies and developments:
6.3.5.1 Approvals:
6.3.5.2 Partnerships, Collaborations, and Agreements:
6.4 Cipla Limited
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Regional Analysis
6.4.4 Research & Development Expense
6.4.5 Recent strategies and developments:
6.4.5.1 Partnerships, Collaborations, and Agreements:
6.4.5.2 Approvals:
6.5 GlaxoSmithKline PLC (GSK)
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Segmental and Regional Analysis
6.5.4 Research & Development Expense
6.6 Mylan N.V.
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Regional Analysis
6.6.4 Research & Development Expense
6.6.5 Recent strategies and developments:
6.6.5.1 Product Launches and Product Expansions:
6.7 Sanofi S.A.
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Segmental and Regional Analysis
6.7.4 Research & Development Expense
6.8 Sun Pharmaceutical Industries Ltd.
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Regional Analysis
6.8.4 Research & Development Expense
6.8.5 Recent strategies and developments:
6.8.5.1 Approvals:
6.8.5.2 Product Launches and Product Expansions:
6.9 Teva Pharmaceutical Industries Ltd.
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Regional Analysis
6.9.4 Research & Development Expenses
6.9.5 Recent strategies and developments:
6.9.5.1 Approvals:
6.9.5.2 Product Launches and Product Expansions:
6.10. Cadila Healthcare Ltd. (Zydus Cadila)
6.10.1 Company Overview
6.10.2 Financial Analysis
6.10.3 Segmental and Regional Analysis
6.10.4 Research & Development Expense
6.10.5 Recent strategies and developments:
6.10.5.1 Approvals:
Unique Offerings 